Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) EBIT Margin (2023)

Contineum Therapeutics (CTNM) has 1 years of EBIT Margin data on record, last reported at 77.87% in Q2 2023.

  • For Q2 2023, EBIT Margin changed N/A year-over-year to 77.87%; the TTM value through Mar 2024 reached 22.52%, changed N/A, while the annual FY2023 figure was 32.15%, N/A changed from the prior year.
  • EBIT Margin reached 77.87% in Q2 2023 per CTNM's latest filing, down from 5559.78% in the prior quarter.
  • Across five years, EBIT Margin topped out at 5559.78% in Q1 2023 and bottomed at 77.87% in Q2 2023.